Brought to you by 
BlueRock Therapeutics launches with $225mm Series A round from Bayer, Versant
09 Aug 2019
Executive Summary
Regenerative medicine start-up BlueRock Therapeutics (induced pluripotent stem cell (iPSC) therapies) was launched with a $225mm Series A investment from Bayer AG (through Leaps by Bayer) and Versant Ventures.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BlueRock Therapeutics launches with $225mm Series A round from Bayer, Versant
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice